| Literature DB >> 14505663 |
Idan Chiyanzu1, Elizabeth Hansell, Jiri Gut, Philip J Rosenthal, James H McKerrow, Kelly Chibale.
Abstract
While commercial isatins were practically inactive against the target proteases, thiosemicarbazone derivatives were found to be active. The most active compound from the series displayed an inhibitory IC(50) value of 1 microM against rhodesain. One thiosemicarbazone was found to be active against all three proteases with inhibitory IC(50) values of 10 microM or less. A combination of N-benzylation and appropriate substitution on the aromatic portion of the isatin scaffold was generally found to be beneficial especially against cruzain for ketone inhibitors.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14505663 DOI: 10.1016/s0960-894x(03)00756-x
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823